DK173085B1 - Fremgangsmåde til bakteriel polypeptidudtrykkelse og plasmidisk udtrykkelsesmedium til fremstilling af et heterologt polype - Google Patents
Fremgangsmåde til bakteriel polypeptidudtrykkelse og plasmidisk udtrykkelsesmedium til fremstilling af et heterologt polype Download PDFInfo
- Publication number
- DK173085B1 DK173085B1 DK198101299A DK129981A DK173085B1 DK 173085 B1 DK173085 B1 DK 173085B1 DK 198101299 A DK198101299 A DK 198101299A DK 129981 A DK129981 A DK 129981A DK 173085 B1 DK173085 B1 DK 173085B1
- Authority
- DK
- Denmark
- Prior art keywords
- polypeptide
- trp
- plasmid
- heterologous
- expression
- Prior art date
Links
- 239000013612 plasmid Substances 0.000 title claims description 116
- 229920001184 polypeptide Polymers 0.000 title claims description 115
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 113
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 112
- 230000014509 gene expression Effects 0.000 title claims description 56
- 230000001580 bacterial effect Effects 0.000 title claims description 13
- 208000037062 Polyps Diseases 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims description 150
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 69
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 69
- 102000004169 proteins and genes Human genes 0.000 claims description 61
- 108020004414 DNA Proteins 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 38
- 241000588724 Escherichia coli Species 0.000 claims description 32
- 150000001413 amino acids Chemical group 0.000 claims description 27
- 239000002131 composite material Substances 0.000 claims description 25
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 239000013598 vector Substances 0.000 claims description 21
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 18
- 108010056088 Somatostatin Proteins 0.000 claims description 18
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 18
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 17
- 239000000854 Human Growth Hormone Substances 0.000 claims description 17
- 102000005157 Somatostatin Human genes 0.000 claims description 17
- 229960000553 somatostatin Drugs 0.000 claims description 17
- 241000894006 Bacteria Species 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 238000013519 translation Methods 0.000 claims description 14
- 102000053602 DNA Human genes 0.000 claims description 10
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims description 8
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 108091033380 Coding strand Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- WTFXTQVDAKGDEY-UHFFFAOYSA-N (-)-chorismic acid Natural products OC1C=CC(C(O)=O)=CC1OC(=C)C(O)=O WTFXTQVDAKGDEY-UHFFFAOYSA-N 0.000 claims description 4
- LXCUAFVVTHZALS-UHFFFAOYSA-N 3-(3-methoxyphenyl)piperidine Chemical compound COC1=CC=CC(C2CNCCC2)=C1 LXCUAFVVTHZALS-UHFFFAOYSA-N 0.000 claims description 4
- WTFXTQVDAKGDEY-HTQZYQBOSA-N Chorismic acid Natural products O[C@@H]1C=CC(C(O)=O)=C[C@H]1OC(=C)C(O)=O WTFXTQVDAKGDEY-HTQZYQBOSA-N 0.000 claims description 4
- 108010076181 Proinsulin Proteins 0.000 claims description 4
- 108010078233 Thymalfasin Proteins 0.000 claims description 3
- 102400000800 Thymosin alpha-1 Human genes 0.000 claims description 3
- 230000000975 bioactive effect Effects 0.000 claims description 3
- 230000001851 biosynthetic effect Effects 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims description 3
- 229960004231 thymalfasin Drugs 0.000 claims description 3
- 230000000994 depressogenic effect Effects 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 238000000855 fermentation Methods 0.000 claims 1
- 230000004151 fermentation Effects 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 88
- 239000012634 fragment Substances 0.000 description 83
- 229960004799 tryptophan Drugs 0.000 description 65
- 235000018102 proteins Nutrition 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 37
- 229930101283 tetracycline Natural products 0.000 description 34
- 239000004098 Tetracycline Substances 0.000 description 30
- 229960002180 tetracycline Drugs 0.000 description 30
- 235000019364 tetracycline Nutrition 0.000 description 30
- 150000003522 tetracyclines Chemical class 0.000 description 30
- 239000000047 product Substances 0.000 description 29
- 238000003776 cleavage reaction Methods 0.000 description 26
- 230000007017 scission Effects 0.000 description 26
- 239000002609 medium Substances 0.000 description 23
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 22
- 108020004705 Codon Proteins 0.000 description 19
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 230000015556 catabolic process Effects 0.000 description 18
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 17
- 229960000723 ampicillin Drugs 0.000 description 17
- 238000006731 degradation reaction Methods 0.000 description 17
- 108091008146 restriction endonucleases Proteins 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 108010046075 Thymosin Proteins 0.000 description 10
- 102000007501 Thymosin Human genes 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- 239000000499 gel Substances 0.000 description 9
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 9
- 101150044170 trpE gene Proteins 0.000 description 9
- 101100122010 Methanocella arvoryzae (strain DSM 22066 / NBRC 105507 / MRE50) glmM gene Proteins 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000013615 primer Substances 0.000 description 8
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 108020004511 Recombinant DNA Proteins 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 6
- 238000012869 ethanol precipitation Methods 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 102000003960 Ligases Human genes 0.000 description 5
- 108090000364 Ligases Proteins 0.000 description 5
- 101710163270 Nuclease Proteins 0.000 description 5
- 101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 5
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 4
- 241001646716 Escherichia coli K-12 Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 101150100816 trpD gene Proteins 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 238000012270 DNA recombination Methods 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000005204 segregation Methods 0.000 description 3
- -1 2-10 times dilution) Chemical compound 0.000 description 2
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 101100269389 Mus musculus Pgm3 gene Proteins 0.000 description 2
- 102000009661 Repressor Proteins Human genes 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 101100046504 Symbiobacterium thermophilum (strain T / IAM 14863) tnaA2 gene Proteins 0.000 description 2
- 239000008051 TBE buffer Substances 0.000 description 2
- 108050004197 Trp repressor Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000001036 exonucleolytic effect Effects 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000006151 minimal media Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000009452 underexpressoin Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- NQEQTYPJSIEPHW-MNOVXSKESA-N (1S,2R)-1-C-(indol-3-yl)glycerol 3-phosphate Chemical compound C1=CC=C2C([C@H](O)[C@@H](COP(O)(O)=O)O)=CNC2=C1 NQEQTYPJSIEPHW-MNOVXSKESA-N 0.000 description 1
- UTWSLTKGFRKQTA-QHPFDFDXSA-N 2-[[(3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-phosphonoamino]benzoic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)OC1N(P(O)(O)=O)C1=CC=CC=C1C(O)=O UTWSLTKGFRKQTA-QHPFDFDXSA-N 0.000 description 1
- SXOUIMVOMIGLHO-UHFFFAOYSA-N 3-(1h-indol-2-yl)prop-2-enoic acid Chemical compound C1=CC=C2NC(C=CC(=O)O)=CC2=C1 SXOUIMVOMIGLHO-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 1
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 101150097493 D gene Proteins 0.000 description 1
- FNZLKVNUWIIPSJ-UHNVWZDZSA-N D-ribulose 5-phosphate Chemical compound OCC(=O)[C@H](O)[C@H](O)COP(O)(O)=O FNZLKVNUWIIPSJ-UHNVWZDZSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 101150013191 E gene Proteins 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FNZLKVNUWIIPSJ-UHFFFAOYSA-N Rbl5P Natural products OCC(=O)C(O)C(O)COP(O)(O)=O FNZLKVNUWIIPSJ-UHFFFAOYSA-N 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000005550 amino acid supplement Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 101150079930 trpGD gene Proteins 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13329680A | 1980-03-24 | 1980-03-24 | |
| US13329680 | 1980-03-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK129981A DK129981A (da) | 1981-09-25 |
| DK173085B1 true DK173085B1 (da) | 1999-12-27 |
Family
ID=22457906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK198101299A DK173085B1 (da) | 1980-03-24 | 1981-03-23 | Fremgangsmåde til bakteriel polypeptidudtrykkelse og plasmidisk udtrykkelsesmedium til fremstilling af et heterologt polype |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US5888808A (cs) |
| EP (3) | EP0086548B1 (cs) |
| JP (3) | JPH0724582B2 (cs) |
| KR (2) | KR830005351A (cs) |
| AR (1) | AR248050A1 (cs) |
| AT (3) | ATE52802T1 (cs) |
| AU (3) | AU542640B2 (cs) |
| BG (3) | BG46005A3 (cs) |
| BR (1) | BR8101712A (cs) |
| CA (2) | CA1198068A (cs) |
| CS (3) | CS238645B2 (cs) |
| DD (3) | DD159435A5 (cs) |
| DE (5) | DE3176205D1 (cs) |
| DK (1) | DK173085B1 (cs) |
| DZ (1) | DZ278A1 (cs) |
| ES (3) | ES500617A0 (cs) |
| FI (3) | FI853488A7 (cs) |
| FR (2) | FR2480781B1 (cs) |
| GB (1) | GB2073203B (cs) |
| GR (1) | GR74818B (cs) |
| HU (1) | HU195534B (cs) |
| IE (3) | IE51894B1 (cs) |
| IL (3) | IL71885A (cs) |
| IT (1) | IT1144324B (cs) |
| MX (1) | MX7689E (cs) |
| MY (1) | MY8500896A (cs) |
| NO (3) | NO810986L (cs) |
| NZ (3) | NZ207660A (cs) |
| OA (1) | OA06774A (cs) |
| PH (4) | PH17537A (cs) |
| PL (2) | PL147727B1 (cs) |
| PT (1) | PT72716B (cs) |
| YU (2) | YU45534B (cs) |
| ZA (1) | ZA811368B (cs) |
| ZW (1) | ZW5481A1 (cs) |
Families Citing this family (368)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1202581A (en) * | 1980-03-27 | 1986-04-01 | Saran A. Narang | Adaptor molecules for dna and their application to synthesis of gene-derived products |
| YU45104B (en) | 1980-04-03 | 1992-03-10 | Biogen Nv | Process for producing recombinant dnk molecule, capable of inducting polypeptide expression in an one-cell host |
| US4874702A (en) * | 1980-09-08 | 1989-10-17 | Biogen, Inc. | Vectors and methods for making such vectors and for expressive cloned genes |
| DK489481A (da) * | 1980-11-10 | 1982-05-11 | Searle & Co | Plasmidvektor og frmgangsmaade til fremstilling deraf |
| US5525484A (en) * | 1981-01-16 | 1996-06-11 | Genome Therapeutics Corp. | Recombinant DNA means and method for producing rennin, prorenin and pre-prorennin |
| BR8205954A (pt) * | 1981-10-14 | 1983-09-13 | Unilever Nv | Sequencia de dna,plasmidio recombinante,cultura bacteriana e microorganismos |
| JPS58110600A (ja) * | 1981-12-25 | 1983-07-01 | Kyowa Hakko Kogyo Co Ltd | ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド |
| JPS58141796A (ja) * | 1982-02-18 | 1983-08-23 | Kyowa Hakko Kogyo Co Ltd | ペプチドの製造法 |
| EP0088994B1 (en) * | 1982-03-15 | 1991-06-19 | Schering Corporation | Hybrid dna, binding composition prepared thereby and processes therefor |
| US4499188A (en) * | 1982-05-05 | 1985-02-12 | Cetus Corporation | Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator |
| US4863855A (en) * | 1982-05-14 | 1989-09-05 | The Research Foundation Of State University Of New York | Novel cloning vehicles for polypeptide expression in microbial hosts |
| EP0108045B1 (en) * | 1982-10-25 | 1988-12-07 | Monsanto Company | Reca promoter dependent polypeptide production |
| CA1252046A (en) * | 1982-11-04 | 1989-04-04 | Martin J. Cline | Methods for oncogenic detection |
| DE3247922A1 (de) * | 1982-12-24 | 1984-06-28 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten |
| DK161152C (da) | 1983-03-03 | 1991-11-11 | Genentech Inc | Polypeptid med egenskaber som human beta-nervevaekstfaktor og fremgangsmaade til fremstilling deraf, dna-isolat omfattende en sekvens som koder for polypeptidet, replicerbar udtrykkelsesvektor for dna-sekvensen, rekombinant vaertscelle transformeret med vektoren, farmaceutisk praeparat indeholdende polypeptidet og fremg. der omfatter anvendelsen af polypeptidet til fremst. af et farmaceutisk praeparat |
| US5169762A (en) * | 1983-03-03 | 1992-12-08 | Genentech, Inc. | Human nerve growth factor by recombinant technology |
| US4701416A (en) * | 1983-12-09 | 1987-10-20 | Cetus Corporation | Feline leukemia virus vaccine plasmids for fusion protein of the gp70 envelope protein of FELV |
| US4935370A (en) * | 1983-12-23 | 1990-06-19 | Pfizer Inc. | Expression plasmids for improved production of heterologous protein in bacteria |
| WO1985003522A1 (en) * | 1984-02-08 | 1985-08-15 | Cetus Corporation | Monitoring and control systems for recombinant manipulations |
| US5028531A (en) * | 1984-03-19 | 1991-07-02 | Fujisawa Pharmaceutical Company, Ltd. | IGF-I fusion proteins; protection of IGF-I from degradation by host cell; and processes for the production thereof |
| GB8407044D0 (en) * | 1984-03-19 | 1984-04-26 | Fujisawa Pharmaceutical Co | Producing human insulin |
| US4894334A (en) * | 1984-03-28 | 1990-01-16 | Cetus Corporation | Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria |
| US4656132A (en) | 1984-03-28 | 1987-04-07 | Cetus Corporation | Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria |
| US5268278A (en) * | 1984-03-30 | 1993-12-07 | Istituto Farmacologico Serono S.P.A. | Genetic expression of somatostatin as hybrid polypeptide |
| US4789702A (en) * | 1984-05-18 | 1988-12-06 | Cetus Corporation | Feline leukemia virus vaccine |
| US5683688A (en) | 1984-05-31 | 1997-11-04 | Genentech, Inc. | Unglycosylated recombinant human lymphotoxin polypeptides and compositions |
| EP0165613B1 (en) * | 1984-06-22 | 1992-01-15 | Hitachi, Ltd. | Process for controlling culture of recombinants |
| JPS619282A (ja) * | 1984-06-22 | 1986-01-16 | Hitachi Ltd | 遺伝子組換え菌の培養方法 |
| JPS6158595A (ja) * | 1984-08-28 | 1986-03-25 | ジェネックス・コーポレイション | 徴生物によるタンパク質規模生産方法 |
| US4738921A (en) * | 1984-09-27 | 1988-04-19 | Eli Lilly And Company | Derivative of the tryptophan operon for expression of fused gene products |
| US5075224A (en) * | 1984-10-19 | 1991-12-24 | Genentech, Inc. | Prepro-LHRH C-terminal peptide DNA |
| NZ213759A (en) * | 1984-10-19 | 1989-01-27 | Genentech Inc | Lhrh-ctp protein conjugates influencing prolactin fsh and lh release |
| FI90990C (fi) * | 1984-12-18 | 1994-04-25 | Boehringer Ingelheim Int | Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi |
| ATE153377T1 (de) | 1985-01-28 | 1997-06-15 | Xoma Corp | Arab-promoter und verfahren zur herstellung von polypeptiden einschliesslich cecropinen mittels mikrobiologischer verfahren |
| IT1234977B (it) * | 1985-03-22 | 1992-06-09 | Serono Ist Farm | Espressione in e. coli polipeptidi ibridi contenenti la sequenza del fattore di rilascio dell'ormone della crescita |
| US4965188A (en) * | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| DK171161B1 (da) * | 1985-03-28 | 1996-07-08 | Hoffmann La Roche | Fremgangsmåde til påvisning af forekomst eller fravær af mindst én specifik nukleinsyresekvens i en prøve eller til skelnen mellem to forskellige nukleinsyresekvenser i denne prøve |
| GB8509289D0 (en) * | 1985-04-11 | 1985-05-15 | Fujisawa Pharmaceutical Co | Production of somatostatin |
| DE3526995A1 (de) * | 1985-07-27 | 1987-02-05 | Hoechst Ag | Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung |
| AU6104586A (en) * | 1985-08-12 | 1987-02-19 | Malcolm A. Martin | Aids protein using trple gene |
| ES2000858A6 (es) * | 1985-08-12 | 1988-03-16 | Syntex Inc | Un metodo para producir un vector de expresion bacteriano para la expresion de proteinas de fusion |
| JPH0775536B2 (ja) * | 1986-03-26 | 1995-08-16 | 猛 小林 | 遺伝子組み換え菌を用いた酵素生産装置 |
| DE3642096A1 (de) * | 1986-12-10 | 1988-06-16 | Boehringer Ingelheim Int | Pferde-(gamma)-interferon |
| US6994988B1 (en) | 1987-02-12 | 2006-02-07 | Genetech, Inc. | Methods and deoxyribonucleic acid for the preparation of tissue factor protein |
| EP0335400B1 (en) * | 1988-03-30 | 1994-06-08 | Hitachi, Ltd. | Processes for production of human epidermal growth factor by genetic engineering |
| JPH01247098A (ja) * | 1988-03-30 | 1989-10-02 | Hitachi Ltd | ヒトの上皮細胞増殖因子の遺伝子工学的生産方法 |
| JPH01247099A (ja) * | 1988-03-30 | 1989-10-02 | Hitachi Ltd | ヒトの上皮細胞増殖因子の遺伝子工学的生産方法 |
| JPH0227993A (ja) * | 1988-07-15 | 1990-01-30 | Nippon Shinyaku Co Ltd | ｈＥＧＦの製法 |
| IL92937A0 (en) | 1989-01-31 | 1990-09-17 | Us Health | Human derived monocyte attracting protein,pharmaceutical compositions comprising it and dna encoding it |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| DE69127829T2 (de) | 1990-11-26 | 1998-03-19 | Chiron Corp., Emeryville, Calif. | Expression von pace in wirtszellen und verfahren zu dessen verwendung |
| WO1993024635A1 (en) | 1992-06-03 | 1993-12-09 | Genentech, Inc. | Tissue plasminogen activator glycosylation variants with improved therapeutic properties |
| GB9325182D0 (en) * | 1993-12-08 | 1994-02-09 | T Cell Sciences Inc | Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions |
| US6001604A (en) * | 1993-12-29 | 1999-12-14 | Bio-Technology General Corp. | Refolding of proinsulins without addition of reducing agents |
| US5629167A (en) | 1994-04-19 | 1997-05-13 | Biocine S.P.A. | Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay |
| US5708142A (en) | 1994-05-27 | 1998-01-13 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
| US7091008B1 (en) | 1994-07-01 | 2006-08-15 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase genes and expression thereof in Bacillus hosts |
| US6455304B1 (en) | 1994-07-01 | 2002-09-24 | The Board Of Regents Of The University Of Oklahoma | Hyaluronate synthase gene and uses thereof |
| US6951743B2 (en) | 1997-10-31 | 2005-10-04 | University Of Oklahoma Board Of Regents | Hyaluronan synthase genes and expression thereof in bacillus hosts |
| US6015660A (en) * | 1995-01-06 | 2000-01-18 | The Regents Of The University Of California | Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases |
| US6077510A (en) * | 1995-01-06 | 2000-06-20 | Regents Of The University Of California | Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases |
| US6113905A (en) * | 1995-01-06 | 2000-09-05 | The Regents Of The University Of California | Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases |
| US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| DE69638346D1 (de) | 1995-06-29 | 2011-05-05 | Immunex Corp | Cytokin welches Apoptose induziert |
| US6020473A (en) * | 1995-08-25 | 2000-02-01 | Genentech, Inc. | Nucleic acids encoding variants of vascular endothelial cell growth factor |
| US7005505B1 (en) | 1995-08-25 | 2006-02-28 | Genentech, Inc. | Variants of vascular endothelial cell growth factor |
| US6998116B1 (en) | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
| US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
| WO1997037020A1 (en) | 1996-04-01 | 1997-10-09 | Genentech, Inc. | Apo-2li and apo-3 apoptosis polypeptides |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US5851984A (en) * | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
| US6159462A (en) * | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
| US6462176B1 (en) | 1996-09-23 | 2002-10-08 | Genentech, Inc. | Apo-3 polypeptide |
| US5990281A (en) * | 1996-09-30 | 1999-11-23 | Genentech, Inc. | Vertebrate smoothened proteins |
| US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
| PT951551E (pt) | 1996-12-23 | 2008-10-28 | Immunex Corp | Ligando para receptor activador de nf-kb, ligando membro da superfamília de tnf |
| WO1998058062A1 (en) | 1997-06-18 | 1998-12-23 | Genentech, Inc. | Apo-2DcR |
| DE69842001D1 (de) * | 1997-04-04 | 2010-12-30 | Univ Southern California | Galvanisches verfahren zur herstellung einer mehrlagenstruktur |
| US6448035B1 (en) | 1997-04-24 | 2002-09-10 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR) |
| US6384203B1 (en) | 1999-05-12 | 2002-05-07 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
| US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| AU739350B2 (en) | 1997-06-05 | 2001-10-11 | University Of Texas System, The | APAF-1, the CED-4 human homolog, an activator of caspase-3 |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| ES2319939T3 (es) | 1997-08-27 | 2009-05-14 | Novartis Vaccines And Diagnostics, Inc. | Mimeticos moleculares de epitopos de meningococos b. |
| US6610838B1 (en) | 1997-09-10 | 2003-08-26 | Symbicom Aktiebolag | P13 antigens from Borrelia |
| ATE393222T1 (de) | 1997-09-18 | 2008-05-15 | Genentech Inc | Dcr3 polypeptid, ein tnfr homolog |
| JP2001522584A (ja) | 1997-10-10 | 2001-11-20 | ジェネンテク・インコーポレイテッド | Ａｐｏ−３リガンドポリペプチド |
| ES2316173T3 (es) | 1997-10-29 | 2009-04-01 | Genentech, Inc. | Genes inducibles por wnt-1. |
| CA2306183A1 (en) | 1997-10-29 | 1999-05-06 | Genentech, Inc. | Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3 |
| CN101113436B (zh) | 1997-10-31 | 2013-02-06 | 俄克拉何马大学董事会 | 透明质酸合酶基因及其应用 |
| EP1025211B1 (en) | 1997-10-31 | 2004-12-15 | The Board of Regents of The University of Oklahoma | Hyaluronan synthase gene and uses thereof |
| EP1029052B1 (en) | 1997-11-06 | 2010-08-04 | Novartis Vaccines and Diagnostics S.r.l. | Neisserial antigens |
| US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
| DK1481989T3 (da) | 1997-11-21 | 2008-08-25 | Genentech Inc | A-33-beslægtede antigener og deres farmakologiske anvendelser |
| ATE446368T1 (de) | 1998-01-14 | 2009-11-15 | Novartis Vaccines & Diagnostic | Antigene aus neisseria meningitidis |
| JP2002508962A (ja) | 1998-01-15 | 2002-03-26 | ジェネンテク・インコーポレイテッド | Ａｐｏ−２リガンド |
| US6727079B1 (en) | 1998-02-25 | 2004-04-27 | The United States Of America As Represented By The Department Of Health And Human Services | cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product |
| EP2050762A3 (en) | 1998-03-10 | 2009-07-08 | Genentech, Inc. | Human cornichon-like protein and nucleic acids encoding it |
| IL138488A0 (en) | 1998-03-17 | 2001-10-31 | Genentech Inc | Polypeptides homologous to vegf and bmp1 |
| US6987023B2 (en) | 1998-04-02 | 2006-01-17 | The Board Of Regents Of The University Of Oklahoma | DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use |
| US7223571B2 (en) | 1998-04-02 | 2007-05-29 | The Board Of Regents Of The Universtiy Of Oklahoma | Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same |
| US20060188966A1 (en) | 1998-04-02 | 2006-08-24 | Deangelis Paul L | Natural, chimeric and hybrid glycosaminoglycan polymers and methods of making and using same |
| GB9808932D0 (en) | 1998-04-27 | 1998-06-24 | Chiron Spa | Polyepitope carrier protein |
| JP5102414B2 (ja) | 1998-05-01 | 2012-12-19 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 髄膜炎菌抗原および組成物 |
| EP3112468A1 (en) | 1998-05-15 | 2017-01-04 | Genentech, Inc. | Il-17 homologous polypeptides and therapeutic uses thereof |
| EP1865061A3 (en) | 1998-05-15 | 2007-12-19 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| IL138930A0 (en) | 1998-05-15 | 2001-11-25 | Genentech Inc | Il-17 homologies polypeptides and therapeutic uses thereof |
| US20020172678A1 (en) | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
| NZ510497A (en) | 1998-08-21 | 2003-09-26 | Immunex Corp | Human IL-1 epsilon DNA and polypeptides |
| KR20010085759A (ko) | 1998-09-03 | 2001-09-07 | 스티븐 비. 데이비스 | 효소산화적 탈아미노화 방법 |
| WO2001051635A2 (en) | 2000-01-13 | 2001-07-19 | Genentech, Inc. | Novel stra6 polypeptides |
| ATE386804T1 (de) | 1998-10-15 | 2008-03-15 | Novartis Vaccines & Diagnostic | Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen |
| US7094581B2 (en) | 1998-10-26 | 2006-08-22 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthases and methods of making and using same |
| DK1141331T3 (da) | 1998-12-16 | 2009-01-05 | Novartis Vaccines & Diagnostic | Human cyclinafhængig kinase (hPNQALRE) |
| CA2450402A1 (en) | 1998-12-22 | 2000-06-29 | Genentech, Inc. | Methods and compositions for inhibiting cancer cell growth comprising pro224 |
| JP5456222B2 (ja) | 1998-12-23 | 2014-03-26 | ジェネンテック， インコーポレイテッド | Ｉｌ−１関連ポリペプチド |
| ES2522667T3 (es) | 1999-04-30 | 2014-11-17 | Novartis Vaccines And Diagnostics S.R.L. | Antígenos Neisseriales conservados |
| GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
| DE60043367D1 (de) | 1999-06-15 | 2009-12-31 | Genentech Inc | Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung |
| US7101989B1 (en) | 1999-07-09 | 2006-09-05 | University Of North Carolina At Chapel Hill | DsrA protein and polynucleotides encoding the same |
| GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
| EP1305412A2 (en) | 1999-10-14 | 2003-05-02 | Clontech Laboratories Inc. | Anthozoa derived chromo/fluoroproteins and methods for using the same |
| NZ531141A (en) | 1999-10-20 | 2005-07-29 | Genentech Inc | Modulation of T cell differentiation for the treatment of T helper cell mediated diseases |
| CA2863668A1 (en) | 1999-10-29 | 2001-05-03 | Novartis Vaccines And Diagnostics S.R.L. | Neisserial antigenic peptides |
| US7078382B1 (en) | 1999-11-02 | 2006-07-18 | Genentech, Inc. | Modulation of eNOS activity and therapeutic uses thereof |
| EP2397031A1 (en) | 1999-11-10 | 2011-12-21 | The University Of Washington | Compositions and methods for modulation of plant cell division |
| EP1672070A3 (en) | 1999-12-01 | 2006-10-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| JP5148795B2 (ja) | 1999-12-20 | 2013-02-20 | イミュネックス・コーポレーション | Ｔｗｅａｋ受容体 |
| EP1897947B1 (en) | 1999-12-23 | 2012-01-18 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| WO2001049859A1 (en) | 1999-12-30 | 2001-07-12 | Genencor International, Inc. | Trichoderma reesei xylanase |
| ES2311016T3 (es) | 2000-01-10 | 2009-02-01 | Novartis Vaccines And Diagnostics, Inc. | Genes expresados diferencialmente en cancer de mama. |
| EP2275129A3 (en) | 2000-01-17 | 2013-11-06 | Novartis Vaccines and Diagnostics S.r.l. | Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins |
| US6992081B2 (en) | 2000-03-23 | 2006-01-31 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
| ES2275675T3 (es) | 2000-03-23 | 2007-06-16 | Elan Pharmaceuticals, Inc. | Compuestos y metodos para tratar la enfermedad de alzheimer. |
| CA2648046A1 (en) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| EP2042597B1 (en) | 2000-06-23 | 2014-05-07 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
| DE60116313T2 (de) | 2000-06-30 | 2006-08-31 | Elan Pharmaceuticals, Inc., San Francisco | Verbindungen zur behandlung der alzheimerischen krankheit |
| US6846813B2 (en) | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
| ATE412009T1 (de) | 2000-08-24 | 2008-11-15 | Genentech Inc | Methode zur inhibierung von il-22 induziertem pap1 |
| EP1944317A3 (en) | 2000-09-01 | 2008-09-17 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2881568C (en) | 2000-10-27 | 2019-09-24 | Novartis Vaccines And Diagnostics, Inc. | Nucleic acids and proteins from streptococcus groups a & b |
| US6673580B2 (en) | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
| AU2002303261A1 (en) | 2001-04-06 | 2002-10-21 | Georgetown University | Gene brcc2 and diagnostic and therapeutic uses thereof |
| AU2002258728A1 (en) | 2001-04-06 | 2002-10-21 | Georgetown University | Gene brcc-3 and diagnostic and therapeutic uses thereof |
| WO2002081641A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene scc-112 and diagnostic and therapeutic uses thereof |
| EP2261241A1 (en) | 2001-04-16 | 2010-12-15 | Wyeth Holdings Corporation | Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| KR100576674B1 (ko) | 2001-06-20 | 2006-05-10 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
| MXPA04000140A (es) | 2001-06-27 | 2004-06-03 | Elan Pharm Inc | Derivados de beta-hidroxiamina utiles en el tratamiento de enfermedad de alzheimer. |
| US6867189B2 (en) | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
| DE60236596D1 (de) | 2001-07-27 | 2010-07-15 | Novartis Vaccines & Diagnostic | Antikörper gegen das meningokokken adhäsin app |
| MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| BR0212070A (pt) | 2001-08-29 | 2004-09-28 | Genentech Inc | ácidos nucléicos e polipeptìdeos bv8 com atividade mitogênica |
| JP2005536439A (ja) | 2001-09-18 | 2005-12-02 | ジェネンテック・インコーポレーテッド | 腫瘍の診断及び治療のための組成物と方法 |
| JP4413617B2 (ja) | 2001-12-12 | 2010-02-10 | カイロン ソチエタ ア レスポンサビリタ リミタータ | Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫化 |
| EP1456223B1 (en) | 2001-12-19 | 2009-08-12 | The University Of Chicago | Rapidly maturing fluorescent proteins and methods for using the same |
| KR20080106369A (ko) | 2002-01-02 | 2008-12-04 | 제넨테크, 인크. | 종양의 진단 및 치료 방법 및 이를 위한 조성물 |
| EP1575480A4 (en) | 2002-02-22 | 2008-08-06 | Genentech Inc | COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM |
| US7244565B2 (en) | 2002-04-10 | 2007-07-17 | Georgetown University | Gene shinc-3 and diagnostic and therapeutic uses thereof |
| US7138512B2 (en) | 2002-04-10 | 2006-11-21 | Georgetown University | Gene SHINC-2 and diagnostic and therapeutic uses thereof |
| JP2005536190A (ja) | 2002-04-16 | 2005-12-02 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
| WO2003099848A2 (en) | 2002-05-24 | 2003-12-04 | Restoragen Inc. | Method for universal enzymatic production of bioactive peptides |
| WO2003099854A2 (en) | 2002-05-24 | 2003-12-04 | Nps Allelix Corp. | Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides |
| EP2305710A3 (en) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetic antibody phage libraries |
| EP1531676B1 (en) | 2002-06-05 | 2015-07-22 | Genentech, Inc. | Compositions and methods for liver growth and liver protection |
| WO2003103725A1 (en) | 2002-06-07 | 2003-12-18 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| CA2489588A1 (en) | 2002-07-08 | 2004-01-15 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP2116551A1 (en) | 2002-09-11 | 2009-11-11 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004024068A2 (en) | 2002-09-11 | 2004-03-25 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
| JP2006515165A (ja) | 2002-09-16 | 2006-05-25 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための新規組成物と方法 |
| EP2500438A3 (en) | 2002-09-25 | 2012-11-28 | Genentech, Inc. | Novel compositions and methods for the treatment of psoriasis |
| EP3109319A1 (en) | 2002-10-04 | 2016-12-28 | Firmenich S.A. | Sesquiterpene synthases and methods of use |
| EP2322200A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| AU2003295401B2 (en) | 2002-11-08 | 2010-04-29 | Genentech, Inc. | Compositions and methods for the treatment of natural killer cell related diseases |
| WO2004046177A2 (en) | 2002-11-15 | 2004-06-03 | Chiron Srl | Unexpected surface proteins in neisseria meningitidis |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| WO2004047728A2 (en) | 2002-11-26 | 2004-06-10 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| AU2004219592C1 (en) | 2003-03-12 | 2011-02-24 | Genentech, Inc. | Use of Bv8 and/or EG-VEGF to promote hematopoiesis |
| KR101195295B1 (ko) | 2003-04-04 | 2012-10-29 | 노파르티스 아게 | 고농도 항체 및 단백질 제형 |
| GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
| JP4850698B2 (ja) | 2003-04-25 | 2012-01-11 | ノース・キャロライナ・ステイト・ユニヴァーシティ | 細胞表面タンパク質相同体をコードするアシドフィルス菌核酸配列及びその使用 |
| ATE504645T1 (de) | 2003-06-23 | 2011-04-15 | Univ North Carolina State | Für fructooligosaccharid-nutzende verbindungen codierende nukleinsäuren aus lactobacillus acidophilus und verwendungen davon |
| ES2424353T3 (es) | 2003-07-08 | 2013-10-01 | Genentech, Inc. | Polipéptidos heterólogos IL-17 A/F y usos terapéuticos de los mismos |
| US7442785B2 (en) | 2003-07-24 | 2008-10-28 | The University Of Kentucky Research Foundation | Sesquiterpene synthase gene and protein |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| CA2539434C (en) | 2003-09-23 | 2014-03-18 | University Of North Carolina At Chapel Hill | Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage |
| EP1673450B1 (en) | 2003-10-14 | 2010-04-28 | Baxter International Inc. | Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives |
| SI2161283T1 (sl) | 2003-11-17 | 2014-10-30 | Genentech, Inc. | Sestavki, ki obsegajo protitelesa proti CD79b, konjugirana na sredstvo, ki inhibira rast, ali na citotoksično sredstvo, in postopki za zdravljenje tumorja hematopoetskega izvora |
| US7829307B2 (en) | 2003-11-21 | 2010-11-09 | Nps Pharmaceuticals, Inc. | Production of glucagon-like peptide 2 |
| KR20060130182A (ko) | 2004-02-02 | 2006-12-18 | 암브룩스, 인코포레이티드 | 변형된 인간 인터페론 폴리펩티드 및 이의 용도 |
| US7459289B2 (en) | 2004-03-08 | 2008-12-02 | North Carolina State University | Lactobacillus acidophilus nucleic acid sequences encoding carbohydrate utilization-related proteins and uses therefor |
| ES2407465T3 (es) | 2004-03-29 | 2013-06-12 | Galpharma Co., Ltd. | Nueva proteína galectina 9 modificada y uso de la misma |
| US7250298B2 (en) | 2004-04-07 | 2007-07-31 | The University Of Chicago | Monomeric red fluorescent proteins |
| JP2008503217A (ja) | 2004-06-18 | 2008-02-07 | アンブレツクス・インコーポレイテツド | 新規抗原結合ポリペプチド及びそれらの使用 |
| WO2006091231A2 (en) | 2004-07-21 | 2006-08-31 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
| CA2583121A1 (en) | 2004-10-21 | 2007-01-04 | Wyeth | Immunogenic compositions of staphylococcus epidermidis polypeptide antigens |
| CA3005835C (en) | 2004-12-22 | 2023-01-31 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| NZ556635A (en) | 2004-12-22 | 2010-11-26 | Genentech Inc | Method for producing soluble multi-membrane-spanning proteins |
| MX2007007580A (es) | 2004-12-22 | 2007-12-11 | Ambrx Inc | Hormona del crecimiento humana modificada. |
| US20090325226A1 (en) | 2005-03-15 | 2009-12-31 | Stafford Darrel W | Methods and Compositions for Producing Active Vitamin K-Dependent Proteins |
| BRPI0609695A2 (pt) | 2005-03-21 | 2011-10-18 | Applera Corp | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para tratar uma doença e uma paciente sofrendo uma terapia |
| CN102212543A (zh) | 2005-04-15 | 2011-10-12 | 北卡罗来纳州大学 | 调节细菌的粘附和应激耐受力的方法和组合物 |
| DE602006020123D1 (de) | 2005-05-04 | 2011-03-31 | Zealand Pharma As | Glucagon-like-peptide-2- (glp-2-) analoga |
| AU2006247591B2 (en) | 2005-05-12 | 2011-12-15 | Zymogenetics, Inc. | Compositions and methods for modulating immune responses |
| US7858843B2 (en) | 2005-06-06 | 2010-12-28 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
| CA2619383C (en) | 2005-07-29 | 2014-09-16 | Targeted Growth, Inc. | Dominant negative mutant krp protein protection of active cyclin-cdk complex inhibition by wild-type krp |
| CA2619577A1 (en) | 2005-08-15 | 2007-02-22 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
| US7666817B2 (en) | 2005-08-31 | 2010-02-23 | The Regents Of The University Of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| DE102005048898A1 (de) | 2005-10-12 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen |
| US8883507B2 (en) | 2005-10-18 | 2014-11-11 | The Regents Of The University Of Colorado | Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells |
| US7749704B2 (en) | 2005-11-01 | 2010-07-06 | Mayo Foundation For Medical Education And Research | Promoter polymorphisms of the BLyS gene and use in diagnostic methods |
| DK2339014T3 (en) | 2005-11-16 | 2015-07-20 | Ambrx Inc | Methods and compositions comprising non-natural amino acids |
| ZA200804162B (en) | 2005-11-21 | 2009-12-30 | Genentech Inc | Novel gene disruptions, compositions and methods relating thereto |
| US8026354B2 (en) | 2005-11-23 | 2011-09-27 | Institut Pasteur | Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| CA2633554C (en) | 2005-12-22 | 2012-11-13 | Genetech, Inc. | Recombinant production of heparin binding proteins |
| US20080311107A1 (en) | 2006-02-17 | 2008-12-18 | Genetech, Inc. | Novel Gene Disruptions, Compositions and Methods Relating Thereto |
| WO2008036437A2 (en) | 2006-04-19 | 2008-03-27 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
| CA2650730A1 (en) | 2006-04-27 | 2007-11-08 | Pikamab, Inc. | Methods and compositions for antibody therapy |
| US20110206692A1 (en) | 2006-06-09 | 2011-08-25 | Novartis Ag | Conformers of bacterial adhesins |
| EP2520586A1 (en) | 2006-06-30 | 2012-11-07 | The Regents of the University of Michigan | Method of producing factor VIII proteins by recombinant methods |
| CA2663083A1 (en) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
| US7985783B2 (en) | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
| CA2668208C (en) | 2006-11-02 | 2017-09-12 | Daniel J. Capon | Hybrid immunoglobulins with moving parts |
| ATE541059T1 (de) | 2007-02-22 | 2012-01-15 | Genentech Inc | Verfahren für den nachweis von entzündlicher darmerkrankung |
| DK2068909T3 (da) | 2007-03-30 | 2012-08-06 | Ambrx Inc | Modificerede FGF-21-polypeptider og anvendelse heraf |
| CA2684750C (en) | 2007-04-20 | 2014-08-05 | Enzon Pharmaceuticals, Inc. | Stable recombinant adenosine deaminase |
| EP2139499A4 (en) | 2007-04-26 | 2010-05-05 | Inspiration Biopharmaceuticals | RECOMBINANT VITAMIN K-DEPENDENT PROTEINS WITH HIGH SIALIC ACID CONTENT AND METHOD FOR THE PRODUCTION THEREOF |
| RU2557319C2 (ru) | 2007-07-16 | 2015-07-20 | Дженентек, Инк. | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ |
| CN101802012B (zh) | 2007-07-16 | 2014-08-06 | 健泰科生物技术公司 | 抗cd79b抗体和免疫偶联物及使用方法 |
| US8293685B2 (en) | 2007-07-26 | 2012-10-23 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗脂肪肝中的应用 |
| WO2009046407A2 (en) | 2007-10-04 | 2009-04-09 | Zymogenetics, Inc. | B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS |
| US20090233991A1 (en) | 2007-11-01 | 2009-09-17 | Hee Cheol Cho | Generation of biological pacemaker activity |
| WO2009059305A2 (en) | 2007-11-01 | 2009-05-07 | The University Of Chicago | Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation |
| MX338336B (es) | 2007-11-20 | 2016-04-07 | Ambrx Inc | Polipeptidos de insulina modificados y sus usos. |
| EP2222700A2 (en) | 2007-11-27 | 2010-09-01 | Medtronic, Inc. | Humanized anti-amyloid beta antibodies |
| WO2009073511A2 (en) | 2007-11-30 | 2009-06-11 | Mayo Foundation For Medical Education And Research | Polymorphisms of the blys gene and use in diagnostic methods |
| BRPI0906435B8 (pt) | 2008-01-31 | 2022-03-15 | Genentech Inc | Anticorpo anti-cd79b quimérico, composto conjugado, formulação farmacêutica, método para determinar a presença da proteína cd79b, ensaio para detectar células de câncer, método para inibir proliferação celular, usos de um anticorpo, de um composto conjugado e de uma formulação farmacêutica, e método para a fabricação de um composto conjugado |
| NZ602170A (en) | 2008-02-08 | 2014-03-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
| EP2245048B1 (en) | 2008-02-21 | 2014-12-31 | Novartis AG | Meningococcal fhbp polypeptides |
| PL3208612T3 (pl) | 2008-04-09 | 2020-03-31 | Genentech, Inc. | Kompozycje i sposoby leczenia chorób o podłożu immunologicznym |
| KR20170078862A (ko) | 2008-05-16 | 2017-07-07 | 타이가 바이오테크놀로지스, 인코포레이티드 | 항체 및 그 제조 방법 |
| PL3225248T3 (pl) | 2008-07-23 | 2023-11-27 | Ambrx, Inc. | Zmodyfikowane polipeptydy bydlęcego G-CSF i ich zastosowania |
| CN104353066B (zh) | 2008-08-28 | 2017-05-10 | 泰加生物工艺学公司 | Myc的调节剂、其使用方法和鉴别调节myc的试剂的方法 |
| CA2737026C (en) | 2008-09-26 | 2019-12-24 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
| AU2009296267B2 (en) | 2008-09-26 | 2013-10-31 | Ambrx, Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
| US9702877B2 (en) | 2008-10-31 | 2017-07-11 | Quest Diagnostics Investments Incorporated | BCR-ABL variants |
| RU2011121042A (ru) | 2008-11-26 | 2013-01-10 | Файв Прайм Терапеутикс, Инк. | Композиции и способы регулирования экспрессии коллагена и актина гладких мышц посредством serpine2 |
| ES2730800T3 (es) | 2009-02-03 | 2019-11-12 | Amunix Pharmaceuticals Inc | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
| BRPI1012676A2 (pt) | 2009-04-01 | 2016-04-05 | Genentech Inc | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso |
| EP2251025A1 (en) | 2009-05-12 | 2010-11-17 | Universitat Autònoma De Barcelona | Use of inclusion bodies as therapeutic agents |
| ITMI20090946A1 (it) | 2009-05-28 | 2010-11-29 | Novartis Ag | Espressione di proteine ricombinanti |
| DK2440241T3 (en) | 2009-06-08 | 2017-10-02 | Amunix Operating Inc | GROWTH HORMON POLYPEPTIDES AND PROCEDURES FOR PREPARING AND USING THEREOF |
| CA2764108A1 (en) | 2009-06-08 | 2010-12-16 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
| WO2011000962A2 (en) | 2009-07-03 | 2011-01-06 | Bionor Immuno As | Novel therapeutic and diagnostic means |
| EP2470670A4 (en) | 2009-08-24 | 2013-07-10 | Amunix Operating Inc | COAGULATION FACTOR VII COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREOF |
| NZ598458A (en) | 2009-08-27 | 2014-03-28 | Novartis Ag | Hybrid polypeptides including meningococcal fhbp sequences |
| WO2011041308A1 (en) | 2009-09-30 | 2011-04-07 | Quest Diagnostics Investments Incorporated | Bcr-abl truncation mutations |
| WO2011042454A1 (en) | 2009-10-06 | 2011-04-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Carbapenemase and antibacterial treatment |
| CA2777717C (en) | 2009-10-15 | 2021-05-25 | Genentech, Inc. | Chimeric fibroblast growth factors with altered receptor specificity |
| WO2011050194A1 (en) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Methods and compositions for modulating hepsin activation of macrophage-stimulating protein |
| WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
| WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
| WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
| AU2010310985B2 (en) | 2009-10-27 | 2014-11-06 | Glaxosmithkline Biologicals S.A. | Modified meningococcal fHBP polypeptides |
| CN102612374A (zh) | 2009-11-12 | 2012-07-25 | 霍夫曼-拉罗奇有限公司 | 提升树突棘密度的方法 |
| EP2507264A2 (en) | 2009-11-30 | 2012-10-10 | F. Hoffmann-La Roche AG | Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid 2) |
| EP2516454A4 (en) | 2009-12-21 | 2013-05-22 | Ambrx Inc | MODIFIED BOVINE SOMATOTROPIN POLYPEPTIDES AND ITS USES |
| BR112012015597A2 (pt) | 2009-12-21 | 2017-01-31 | Ambrx Inc | peptídeos de somatotropina suínos modificados e seus usos |
| FR2954349A1 (fr) | 2009-12-22 | 2011-06-24 | Agronomique Inst Nat Rech | Sulfatase modifiant selectivement les glycosaminoglycanes |
| MX2012009215A (es) | 2010-02-23 | 2012-11-23 | Genentech Inc | Composiciones y metodos para el diagnostico y tratamiento de tumores. |
| ES2993140T3 (en) | 2010-04-02 | 2024-12-23 | Amunix Pharmaceuticals Inc | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| MA34291B1 (fr) | 2010-05-03 | 2013-06-01 | Genentech Inc | Compositions et méthodes de diagnostic et de traitement d'une tumeur |
| WO2011146715A1 (en) | 2010-05-19 | 2011-11-24 | North Carolina State University | Compositions and methods for the delivery of therapeutic peptides |
| WO2011149461A1 (en) | 2010-05-27 | 2011-12-01 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
| US20130150286A1 (en) | 2010-06-25 | 2013-06-13 | Jean-Claude Sirard | Methods and pharmaceutical compositions for the treatment of respiratory tract infections |
| MX360097B (es) | 2010-07-29 | 2018-10-22 | Eleven Biotherapeutics Inc | Agonistas y antagonistas del receptor tipo i de il-1 quimérico. |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| NZ607069A (en) | 2010-08-17 | 2014-10-31 | Ambrx Inc | Modified relaxin polypeptides and their uses |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| US8729233B2 (en) | 2010-08-30 | 2014-05-20 | Board Of Trustees Of Michigan State University | Microbial nanowires and products related thereto |
| CN102380091A (zh) | 2010-08-31 | 2012-03-21 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗病毒性肝炎中的应用 |
| WO2012036884A2 (en) | 2010-09-15 | 2012-03-22 | Aligna Technologies, Inc. | Bioproduction of aromatic chemicals from lignin-derived compounds |
| AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
| US20150139991A1 (en) | 2010-10-15 | 2015-05-21 | Leadartis, S.L. | Generation of multifunctional and multivalent polypeptide complexes with collagen xviii trimerization domain |
| EP2441776A1 (en) | 2010-10-15 | 2012-04-18 | Leadartis, S.L. | Generation of multifunctional and multivalent polypeptide complexes with collagen XVIII trimerization domain |
| EP2655607A4 (en) | 2010-12-21 | 2014-05-14 | Univ North Carolina | METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS |
| US8603740B2 (en) | 2010-12-29 | 2013-12-10 | Quest Diagnostics Investments Incorporated | BCR-ABL1 splice variants and uses thereof |
| WO2012095684A1 (en) | 2011-01-10 | 2012-07-19 | Inserm ( Institut National De La Sante Et De La Recherche Medicale) | Methods for the screening of substances useful for the prevention and treatment of neisseria infections |
| WO2012103240A2 (en) | 2011-01-25 | 2012-08-02 | Eleven Biotherapeutics, Inc. | Receptor binding agents |
| CN103533951B (zh) | 2011-04-08 | 2017-04-19 | 安姆根有限公司 | 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法 |
| WO2013011072A1 (en) | 2011-07-20 | 2013-01-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Carbapenemase and antibacterial treatment |
| EP2736524A1 (en) | 2011-07-29 | 2014-06-04 | Eleven Biotherapeutics, Inc. | Purified proteins |
| WO2013033456A2 (en) | 2011-09-02 | 2013-03-07 | Board Of Trustees Of Michigan State University | Microbial nanowires and methods of making and using |
| KR20140125803A (ko) | 2012-01-26 | 2014-10-29 | 암젠 인크 | 성장 분화 인자 15(gdf-15) 폴리펩타이드들 |
| EP2822577B1 (en) | 2012-02-15 | 2019-02-06 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
| SI2814840T1 (sl) | 2012-02-15 | 2020-06-30 | Bioverativ Therapeutics Inc. | Sestavki faktorja VIII in postopki njihove izdelave in uporabe |
| EA030911B1 (ru) | 2012-02-27 | 2018-10-31 | Амуникс Оперейтинг Инк. | Композиции конъюгата xten и способы их получения |
| SG11201406112TA (en) | 2012-03-27 | 2014-10-30 | Genentech Inc | Improved harvest operations for recombinant proteins |
| AU2013251375B2 (en) | 2012-04-27 | 2017-06-15 | Donald P. Bottaro | Vascular endothelial growth factor antagonists and methods for their use |
| WO2013164484A1 (en) | 2012-05-03 | 2013-11-07 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues |
| CA2874936A1 (en) | 2012-06-06 | 2013-12-12 | Bionor Immuno As | Vaccine |
| DK2877189T3 (da) | 2012-07-20 | 2021-02-22 | Taiga Biotechnologies Inc | Forbedret rekonstituering og autorekonstituering af det hæmopoietiske kammer |
| EP2882844B1 (en) | 2012-08-10 | 2018-10-03 | Cytomx Therapeutics Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| AU2013348029A1 (en) | 2012-11-20 | 2015-07-02 | The University Of North Carolina At Chapel Hill | Methods and compositions for modified factor IX proteins |
| BR112015012986A2 (pt) | 2012-12-07 | 2017-09-12 | Danisco Us Inc | composições e métodos de uso |
| US9879245B2 (en) | 2012-12-07 | 2018-01-30 | Danisco Us Inc. | Polypeptides having beta-mannanase activity and methods of use |
| US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| AU2014243839B2 (en) | 2013-03-13 | 2019-01-03 | Buzzard Pharmaceuticals AB | Chimeric cytokine formulations for ocular delivery |
| WO2014145016A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
| PT3611180T (pt) | 2013-03-15 | 2022-03-15 | Biomolecular Holdings Llc | Imunoglobulina híbrida que contém uma ligação não peptídica |
| WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
| TWI667255B (zh) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途 |
| WO2015059690A1 (en) | 2013-10-24 | 2015-04-30 | Yeda Research And Development Co. Ltd. | Polynucleotides encoding brex system polypeptides and methods of using s ame |
| CA2928526A1 (en) | 2013-11-01 | 2015-05-07 | Spherium Biomed S.L. | Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents |
| CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术（上海）有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
| WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
| LT3701971T (lt) | 2014-03-14 | 2023-01-10 | Biomolecular Holdings Llc | Junginiai, naudingi hibridinio imunoglobulino, turinčio nepeptidilo ryšį, gamyboje |
| JP2017523166A (ja) | 2014-07-11 | 2017-08-17 | ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ | ヒト免疫不全ウイルスｉ（ｈｉｖ）の病理学的影響を減少及び／若しくは遅延させるか又は後天性免疫不全症候群（ａｉｄｓ）を発症するリスクを低減させる方法 |
| US20170218351A1 (en) | 2014-09-30 | 2017-08-03 | Danisco Us Inc. | Compositions comprising beta-mannanase and methods of use |
| WO2016054168A1 (en) | 2014-09-30 | 2016-04-07 | Danisco Us Inc | Compositions comprising beta mannanase and methods of use |
| WO2016054176A1 (en) | 2014-09-30 | 2016-04-07 | Danisco Us Inc | Compositions comprising beta-mannanase and methods of use |
| WO2016054194A1 (en) | 2014-09-30 | 2016-04-07 | 1/1Danisco Us Inc | Compositions comprising beta-mannanase and methods of use |
| US20170211054A1 (en) | 2014-09-30 | 2017-07-27 | Dansico Us Inc. | Compositions comprising beta mannanase and methods of use |
| WO2016065326A2 (en) | 2014-10-24 | 2016-04-28 | Bristol-Myers Squibb Company | Modified fgf-21 polypeptides and uses thereof |
| US20180002683A1 (en) | 2014-12-18 | 2018-01-04 | Danisco Us Inc. | Engineered multifunctional enzymes and methods of use |
| US20170362621A1 (en) | 2014-12-18 | 2017-12-21 | Danisco Us Inc. | Engineered multifunctional enzymes and methods of use |
| CN114106146B (zh) | 2015-02-06 | 2025-05-06 | 北卡罗来纳大学查珀尔希尔分校 | 优化的人类凝血因子viii基因表达盒及其用途 |
| PT3277821T (pt) | 2015-03-31 | 2019-10-31 | Novimmune Sa | Método para otimizar a montagem e produção de complexos proteicos hetero-multiméricos |
| CA2984991A1 (en) | 2015-05-04 | 2016-11-10 | Bionor Immuno As | Dosage regimen for hiv vaccine |
| AU2016301303B2 (en) | 2015-08-03 | 2021-10-07 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| CA3019373A1 (en) | 2016-03-29 | 2017-10-05 | Geltor, Inc. | Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1 |
| ES2930351T3 (es) | 2016-04-15 | 2022-12-09 | Evive Biotechnology Shanghai Ltd | Un dímero de IL-22 para su uso en el tratamiento de enterocolitis necrosante |
| US10590426B2 (en) | 2016-08-22 | 2020-03-17 | Board Of Trustees Of Michigan State University | Genetic control of cell size |
| CA3045017A1 (en) | 2016-12-02 | 2018-06-07 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
| CA3046207A1 (en) | 2016-12-06 | 2018-06-14 | Kaleido Biosciences, Inc. | Glycan polymers and related methods thereof |
| IL250479A0 (en) | 2017-02-06 | 2017-03-30 | Sorek Rotem | Genetically engineered cells expressing a disarm system that confers resistance to phages and methods for their production |
| AU2018219283B2 (en) | 2017-02-08 | 2022-05-19 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
| WO2018152496A1 (en) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions and methods for the diagnosis and treatment of zika virus infection |
| US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
| AU2017425657A1 (en) | 2017-08-03 | 2020-02-13 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
| US11180541B2 (en) | 2017-09-28 | 2021-11-23 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
| BR112020013420A2 (pt) | 2018-01-26 | 2020-12-01 | Genentech, Inc. | composições, métodos para tratar doença, para inibir infecção, para tratar lesão, para acelerar ou aprimorar cura, para prevenir ou tratar uma afecção, para tratar síndrome, para tratar endotoxemia, para produzir uma composição, para selecionar um lote, para controlar o teor de ácido e uso |
| JP7345479B2 (ja) | 2018-01-26 | 2023-09-15 | ジェネンテック， インコーポレイテッド | 組成物及び使用方法 |
| KR20200123118A (ko) | 2018-02-21 | 2020-10-28 | 제넨테크, 인크. | IL-22 Fc 융합 단백질로 치료를 위한 투약 |
| IL258467A (en) | 2018-03-29 | 2018-07-04 | Ilana Kolodkin Gal | Methods of disrupting a biofilm and/or preventing formation of same |
| JOP20200258A1 (ar) | 2018-04-09 | 2020-10-11 | Amgen Inc | البروتينات الاندماجية لعامل تمايز النمو 15 |
| RS66972B1 (sr) | 2018-05-18 | 2025-07-31 | Bioverativ Therapeutics Inc | Metode lečenja hemofilije a |
| EP3802601A1 (en) | 2018-06-06 | 2021-04-14 | Leadartis, S.L. | Trimeric polypeptide complexes and uses thereof |
| US12049485B2 (en) | 2018-09-11 | 2024-07-30 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
| US12419902B2 (en) | 2019-03-31 | 2025-09-23 | Yeda Research And Development Co. Ltd. | Anti-viral and anti-tumoral compounds |
| CN113874033A (zh) | 2019-04-08 | 2021-12-31 | 泰加生物工艺学公司 | 用于冷冻保存免疫细胞的组合物和方法 |
| JP2022526434A (ja) | 2019-04-12 | 2022-05-24 | ジェルター， インコーポレイテッド | 組換えエラスチンおよびその産生 |
| SG11202112529WA (en) | 2019-05-14 | 2021-12-30 | Taiga Biotechnologies Inc | Compositions and methods for treating t cell exhaustion |
| KR102134418B1 (ko) * | 2019-06-17 | 2020-07-16 | 씨제이제일제당 주식회사 | L-타이로신을 생산하는 미생물 및 이를 이용한 l-타이로신 생산 방법 |
| US20210070811A1 (en) | 2019-09-05 | 2021-03-11 | Board Of Trustees Of Michigan State University | Method for protein nanowire synthesis and tunable control of nanowire length |
| CN115243726B (zh) | 2020-03-11 | 2025-07-15 | 北京泰德制药股份有限公司 | 白介素-2多肽偶联物及其使用方法 |
| WO2021207662A1 (en) | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
| IL288680A (en) | 2021-12-05 | 2023-07-01 | Yeda Res & Dev | Genetically modified phages and their use |
| WO2024133316A1 (en) | 2022-12-23 | 2024-06-27 | Thermo Fisher Scientific Baltics Uab | Closed system for expressing recombinant proteins using e. coli and methods for producing clarified cell cultures thereof |
| WO2024175780A1 (en) | 2023-02-23 | 2024-08-29 | Micropep Technologies S.A. | Micropeptides to improve plant immunity and application thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4237224A (en) * | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
| US4366246A (en) * | 1977-11-08 | 1982-12-28 | Genentech, Inc. | Method for microbial polypeptide expression |
| NO783722L (no) * | 1977-11-08 | 1979-05-09 | Genentech Inc | Rekombinant-plasmid samt fremgangsmaate til dets fremstilling |
| US4631257A (en) | 1978-12-26 | 1986-12-23 | Cetus Corporation | Stable high copy number plasmids |
| FI793884A7 (fi) * | 1978-12-26 | 1981-01-01 | Cetus Corp | Vakaita runsaasti jäljentyviä plasmideja. |
| US4332892A (en) | 1979-01-15 | 1982-06-01 | President And Fellows Of Harvard College | Protein synthesis |
| AU542264B2 (en) * | 1979-06-01 | 1985-02-14 | G.D. Searle & Co. | Plasmid vectors |
| US4342832A (en) * | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
| GB2068970B (en) * | 1980-02-06 | 1983-06-22 | Searle & Co | Recombinant dna technique for the preparation of a protein resembling human interferon |
| DK33181A (da) * | 1980-02-06 | 1981-08-07 | Searle & Co | Fremgangsmaade til fremstilling af et interferonlignende protein |
| CH651308A5 (de) * | 1980-07-01 | 1985-09-13 | Hoffmann La Roche | Interferone und deren herstellung. |
| NZ198445A (en) * | 1980-09-25 | 1984-05-31 | Genentech Inc | Production of human fibroblast interferon by recombinant dna technology |
| JPS5780398A (en) * | 1980-11-05 | 1982-05-19 | Sanraku Inc | Plasmid produced by genetic manipulation, coliform bacillus having the same and preparation of tryptophan with said bacillus |
| DK489481A (da) * | 1980-11-10 | 1982-05-11 | Searle & Co | Plasmidvektor og frmgangsmaade til fremstilling deraf |
| US5145782A (en) * | 1980-12-08 | 1992-09-08 | The Regents Of The University Of California | DNA expression vector suitable for direct expression of a foreign gene |
| EP0054330B1 (en) * | 1980-12-12 | 1986-09-17 | Unilever N.V. | Dna sequences encoding various allelic forms of mature thaumatin, recombinant plasmids comprising said dna's and a process for their preparation, bacterial cultures comprising said recombinant plasmids, and method for producing mature thaumatin |
-
1981
- 1981-03-02 ZA ZA00811368A patent/ZA811368B/xx unknown
- 1981-03-03 BG BG078443A patent/BG46005A3/xx unknown
- 1981-03-13 ZW ZW54/81A patent/ZW5481A1/xx unknown
- 1981-03-20 FI FI853488A patent/FI853488A7/fi not_active Application Discontinuation
- 1981-03-20 FI FI810876A patent/FI810876A7/fi not_active Application Discontinuation
- 1981-03-20 CA CA000373565A patent/CA1198068A/en not_active Expired
- 1981-03-20 GR GR64454A patent/GR74818B/el unknown
- 1981-03-23 NZ NZ207660A patent/NZ207660A/en unknown
- 1981-03-23 JP JP56040529A patent/JPH0724582B2/ja not_active Expired - Lifetime
- 1981-03-23 AT AT85100548T patent/ATE52802T1/de not_active IP Right Cessation
- 1981-03-23 EP EP83200301A patent/EP0086548B1/en not_active Expired
- 1981-03-23 IE IE657/86A patent/IE51894B1/en not_active IP Right Cessation
- 1981-03-23 FR FR8105732A patent/FR2480781B1/fr not_active Expired
- 1981-03-23 DE DE8383200301T patent/DE3176205D1/de not_active Expired
- 1981-03-23 CS CS816230A patent/CS238645B2/cs unknown
- 1981-03-23 AU AU68636/81A patent/AU542640B2/en not_active Expired
- 1981-03-23 AT AT81301227T patent/ATE34183T1/de active
- 1981-03-23 BR BR8101712A patent/BR8101712A/pt not_active IP Right Cessation
- 1981-03-23 EP EP81301227A patent/EP0036776B1/en not_active Expired
- 1981-03-23 HU HU81732A patent/HU195534B/hu unknown
- 1981-03-23 CS CS812106A patent/CS238612B2/cs unknown
- 1981-03-23 CS CS816231A patent/CS238646B2/cs unknown
- 1981-03-23 DE DE3153606A patent/DE3153606C2/de not_active Expired - Lifetime
- 1981-03-23 DE DE8181301227T patent/DE3176737D1/de not_active Expired
- 1981-03-23 IL IL71885A patent/IL71885A/xx not_active IP Right Cessation
- 1981-03-23 AR AR81284705A patent/AR248050A1/es active
- 1981-03-23 ES ES500617A patent/ES500617A0/es active Granted
- 1981-03-23 PT PT72716A patent/PT72716B/pt unknown
- 1981-03-23 DK DK198101299A patent/DK173085B1/da active
- 1981-03-23 AT AT83200301T patent/ATE27306T1/de not_active IP Right Cessation
- 1981-03-23 IT IT67406/81A patent/IT1144324B/it active
- 1981-03-23 PH PH25398A patent/PH17537A/en unknown
- 1981-03-23 DD DD81228534A patent/DD159435A5/de unknown
- 1981-03-23 IL IL62460A patent/IL62460A/xx not_active IP Right Cessation
- 1981-03-23 BG BG078444A patent/BG45220A3/xx unknown
- 1981-03-23 DE DE8585100548T patent/DE3177179D1/de not_active Expired - Lifetime
- 1981-03-23 GB GB8108986A patent/GB2073203B/en not_active Expired
- 1981-03-23 DD DD81243409A patent/DD204494A5/de unknown
- 1981-03-23 IE IE636/81A patent/IE51892B1/en not_active IP Right Cessation
- 1981-03-23 YU YU756/81A patent/YU45534B/xx unknown
- 1981-03-23 KR KR1019810000949A patent/KR830005351A/ko not_active Ceased
- 1981-03-23 NZ NZ207659A patent/NZ207659A/en unknown
- 1981-03-23 DD DD81243408A patent/DD203746A5/de unknown
- 1981-03-23 DE DE19813111405 patent/DE3111405A1/de active Granted
- 1981-03-23 NZ NZ196584A patent/NZ196584A/en unknown
- 1981-03-23 BG BG051341A patent/BG42526A3/xx unknown
- 1981-03-23 EP EP85100548A patent/EP0154133B1/en not_active Expired - Lifetime
- 1981-03-23 NO NO810986A patent/NO810986L/no unknown
- 1981-03-23 OA OA57360A patent/OA06774A/xx unknown
- 1981-03-23 IE IE656/86A patent/IE51893B1/en not_active IP Right Cessation
- 1981-03-24 MX MX81101935U patent/MX7689E/es unknown
- 1981-03-24 PL PL1981252630A patent/PL147727B1/pl unknown
- 1981-03-24 DZ DZ816135A patent/DZ278A1/fr active
- 1981-03-24 PL PL81230296A patent/PL162227B1/pl unknown
-
1982
- 1982-02-26 ES ES509935A patent/ES509935A0/es active Granted
- 1982-02-26 ES ES509936A patent/ES509936A0/es active Granted
- 1982-11-12 PH PH28135A patent/PH20736A/en unknown
- 1982-11-12 PH PH28133A patent/PH18915A/en unknown
- 1982-11-12 PH PH28134A patent/PH20110A/en unknown
-
1984
- 1984-02-14 YU YU00260/84A patent/YU26084A/xx unknown
- 1984-05-21 IL IL71885A patent/IL71885A0/xx unknown
- 1984-06-27 AU AU29964/84A patent/AU580959B2/en not_active Expired
- 1984-06-27 AU AU29963/84A patent/AU585832B2/en not_active Expired
- 1984-09-18 NO NO84843719A patent/NO165644C/no not_active IP Right Cessation
- 1984-09-18 NO NO84843718A patent/NO161572C/no not_active IP Right Cessation
- 1984-12-19 FR FR8419450A patent/FR2555199B1/fr not_active Expired
-
1985
- 1985-05-21 CA CA000482003A patent/CA1213539A/en not_active Expired
- 1985-09-12 FI FI853489A patent/FI72344C/fi not_active IP Right Cessation
- 1985-12-30 MY MY896/85A patent/MY8500896A/xx unknown
-
1986
- 1986-03-29 KR KR1019860002404A patent/KR860001230B1/ko not_active Expired
-
1992
- 1992-10-13 JP JP4274165A patent/JPH0673469B2/ja not_active Expired - Lifetime
- 1992-10-13 JP JP4274172A patent/JPH0734747B2/ja not_active Expired - Lifetime
-
1993
- 1993-04-29 US US08/055,960 patent/US5888808A/en not_active Expired - Lifetime
-
1995
- 1995-06-06 US US08/482,321 patent/US6333174B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK173085B1 (da) | Fremgangsmåde til bakteriel polypeptidudtrykkelse og plasmidisk udtrykkelsesmedium til fremstilling af et heterologt polype | |
| EP0075444B1 (en) | Methods and products for facile microbial expression of dna sequences | |
| DK170477B1 (da) | Mikrobiel hybrid promotor/operator, vektor og udtrykkelsesvektor indeholdende denne, og E. coli stamme transformeret med udtrykkelsesvektoren, kultur af E. coli stammen og fremgangsmåde til mikrobiel produktion af heterologe polypeptider under anvendelse af kulturen | |
| US4663283A (en) | Method of altering double-stranded DNA | |
| EP0104061A1 (en) | Improved expression vectors | |
| EP0040466B1 (en) | Adaptor molecules for dna and their application to synthesis of gene-derived products | |
| EP0179786B1 (en) | High copy number expression vectors | |
| IE53607B1 (en) | Expression vectors | |
| CA2057715A1 (en) | Method for enhancing the structural stability of recombinant dna expression vectors | |
| DK173822B1 (da) | Fremgangsmåde til fremstilling af bovint væksthormon | |
| EP0197558A2 (en) | Process for production of somatostatin |